. TEM images of (a) PCN-224, (b) Fe(VI)@PCN-224 and (c) Fe(VI)@PCN@BSA nanoparticles, and (d) elemental mapping of Fe(VI)@PCN@BSA nanoparticles
. XRD patterns of K2FeO4, PCN-224, Fe(VI)@PCN-224, and Fe(VI)@PCN@BSA nanoparticles
. DLS size distributions of (a) PCN-224, (b) Fe(VI)@PCN-224 and (c) Fe(VI)@PCN@BSA nanoparticles, and (d) Zeta potentials of BSA, PCN-224, Fe(VI)@PCN, and Fe(VI)@PCN@BSA nanoparticles
. Changes of (a) size and (b) Zeta potential of Fe(VI)@PCN@BSA nanoparticles in H2O, PBS and DEME
. (a) UV-Vis absorption spectra of PCN-224, Fe(VI)@PCN-224, and Fe(VI)@PCN@BSA suspensions (inset is pictures of the suspensions), and (b) Fourier transform infrared spectra of BSA, PCN-224, Fe(VI)@PCN-224, and Fe(VI)@PCN@BSA nanoparticles
. Chemodynamic properties of Fe(VI)@PCN@BSA nanoparticles
. Changes of dissolved O2 in NaAc solutions under (a) pH 6.0 and (b) pH 7.4 with different H2O2 concentrations after the addition of Fe(VI)@PCN@BSA nanoparticles (50 μg/mL)
. (a-c) UV-Vis absorbance spectra of the DPBF solutions with Fe(VI)@PCN@BSA nanoparticles (50 μg/mL) and (d) absorbance changes of DPBF solutions at 439 nm for different groups
. Cell viabilities of MDA-MB-231 cells and human dermal fibroblasts after 24 h incubation with Fe(VI)@PCN@BSA nanoparticles at different concentrations
. Fluorescence images of MDA-MB-231 cells after different treatments for observing intracellular ROS
. Synergistic therapeutic effect of Fe(VI)@PCN@BSA nanoparticles on MDA-MB-231 cells (*P < 0.05, **P < 0.01, ***P < 0.001)